News on immunohistochemistry and other tissue-based testing methods.
Bio-Techne said pathologists now have access to its fully automated RNAscope technology, providing them with a new tool to evaluate disease biomarkers.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The La Jolla, California-based developer of genomic melanoma tests posted nearly $1.6 million in revenues in Q4, up from $600,000 in Q4 2018.
Both deals involve the Inspirata's steps to expand partnerships for its digital pathology solution, the Dynamyx case management platform.
